Joseph Catanzaro
Stock Analyst at Mizuho Securities
(4.60)
# 944
Out of 5,060 analysts
419
Total ratings
45.8%
Success rate
12%
Average return
Main Sectors:
Stocks Rated by Joseph Catanzaro
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVTX Avalo Therapeutics | Rated: Hold | n/a | $11.27 | - | 4 | Sep 4, 2026 | |
| BCAX Bicara Therapeutics | Rated: Hold | n/a | $16.78 | - | 3 | Sep 4, 2026 | |
| CLDX Celldex Therapeutics | Rated: Hold | n/a | $27.53 | - | 4 | Sep 4, 2026 | |
| ERAS Erasca | Rated: Hold | n/a | $13.39 | - | 5 | Sep 4, 2026 | |
| KYMR Kymera Therapeutics | Rated: Hold | n/a | $104.78 | - | 4 | Sep 4, 2026 | |
| NRIX Nurix Therapeutics | Rated: Hold | n/a | $24.42 | - | 28 | Sep 4, 2026 | |
| RVMD Revolution Medicines | Rated: Hold | n/a | $177.96 | - | 18 | Sep 4, 2026 | |
| SYRE Spyre Therapeutics | Rated: Hold | n/a | $79.90 | - | 5 | Sep 4, 2026 | |
| TNGX Tango Therapeutics | Rated: Hold | n/a | $22.04 | - | 10 | Sep 4, 2026 | |
| UPB Upstream Bio | Rated: Hold | n/a | $2.76 | - | 3 | Sep 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 → $36 | $7.52 | +378.72% | 2 | Jul 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $50 | $10.94 | +357.04% | 1 | Apr 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $18 | $9.82 | +83.30% | 1 | Apr 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $26 | $7.42 | +250.40% | 1 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $4.5 | $0.244 | n/a | 6 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $36 → $38 | $3.28 | n/a | 5 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $3.25 | $2.28 | n/a | 15 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $53 | $121.84 | n/a | 27 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $4.75 → $4.25 | $9.18 | n/a | 15 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $0.9011 | n/a | 16 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $7.5 → $6 | $13.62 | n/a | 37 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 → $45 | $22.60 | n/a | 5 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $37 → $38 | $62.23 | n/a | 11 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $105 → $110 | $156.19 | n/a | 20 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $15 → $3 | $2.57 | n/a | 15 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $40 → $15 | $10.66 | n/a | 25 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $19 | $6.73 | n/a | 2 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 → $19 | $0.8689 | n/a | 17 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $15 | $1.72 | n/a | 10 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $30 | $1.64 | n/a | 8 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 → $8 | $1.26 | n/a | 9 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $5 → $1.75 | $2.89 | n/a | 9 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $20 | $2.33 | n/a | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 | $6.87 | n/a | 39 | Apr 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $15 → $1.75 | $0.6266 | n/a | 8 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $1.5 → $1.75 | $0.9063 | n/a | 4 | Sep 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 | $1.04 | n/a | 3 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 | $23.25 | n/a | 4 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 → $4 | $18.80 | n/a | 4 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $45 → $36 | $19.12 | n/a | 4 | Mar 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 → $17 | $0.9901 | n/a | 7 | Aug 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $28 → $18 | $2.12 | n/a | 4 | Apr 7, 2020 |
Avalo Therapeutics
Sep 4, 2026
Rated: Hold
Price Target: n/a
Current: $11.27
Upside: -
Bicara Therapeutics
Sep 4, 2026
Rated: Hold
Price Target: n/a
Current: $16.78
Upside: -
Celldex Therapeutics
Sep 4, 2026
Rated: Hold
Price Target: n/a
Current: $27.53
Upside: -
Erasca
Sep 4, 2026
Rated: Hold
Price Target: n/a
Current: $13.39
Upside: -
Kymera Therapeutics
Sep 4, 2026
Rated: Hold
Price Target: n/a
Current: $104.78
Upside: -
Nurix Therapeutics
Sep 4, 2026
Rated: Hold
Price Target: n/a
Current: $24.42
Upside: -
Revolution Medicines
Sep 4, 2026
Rated: Hold
Price Target: n/a
Current: $177.96
Upside: -
Spyre Therapeutics
Sep 4, 2026
Rated: Hold
Price Target: n/a
Current: $79.90
Upside: -
Tango Therapeutics
Sep 4, 2026
Rated: Hold
Price Target: n/a
Current: $22.04
Upside: -
Upstream Bio
Sep 4, 2026
Rated: Hold
Price Target: n/a
Current: $2.76
Upside: -
Jul 13, 2026
Reiterated: Buy
Price Target: $14 → $36
Current: $7.52
Upside: +378.72%
Apr 30, 2026
Initiated Coverage: Buy
Price Target: $50
Current: $10.94
Upside: +357.04%
Apr 15, 2026
Initiated Coverage: Buy
Price Target: $18
Current: $9.82
Upside: +83.30%
Mar 2, 2026
Initiated Coverage: Buy
Price Target: $26
Current: $7.42
Upside: +250.40%
Mar 21, 2025
Reiterated: Buy
Price Target: $4.5
Current: $0.244
Upside: n/a
Mar 20, 2025
Reiterated: Buy
Price Target: $36 → $38
Current: $3.28
Upside: n/a
Mar 7, 2025
Reiterated: Buy
Price Target: $3.25
Current: $2.28
Upside: n/a
Mar 6, 2025
Reiterated: Hold
Price Target: $53
Current: $121.84
Upside: n/a
Mar 3, 2025
Reiterated: Hold
Price Target: $4.75 → $4.25
Current: $9.18
Upside: n/a
Feb 28, 2025
Reiterated: Buy
Price Target: $10
Current: $0.9011
Upside: n/a
Feb 28, 2025
Reiterated: Hold
Price Target: $7.5 → $6
Current: $13.62
Upside: n/a
Feb 27, 2025
Reiterated: Buy
Price Target: $50 → $45
Current: $22.60
Upside: n/a
Feb 12, 2025
Reiterated: Buy
Price Target: $37 → $38
Current: $62.23
Upside: n/a
Feb 12, 2025
Reiterated: Buy
Price Target: $105 → $110
Current: $156.19
Upside: n/a
Jan 29, 2025
Rated: Buy
Price Target: $15 → $3
Current: $2.57
Upside: n/a
Jan 17, 2025
Reiterated: Buy
Price Target: $40 → $15
Current: $10.66
Upside: n/a
Nov 6, 2024
Rated: Buy
Price Target: $19
Current: $6.73
Upside: n/a
Oct 31, 2024
Reiterated: Buy
Price Target: $10 → $19
Current: $0.8689
Upside: n/a
Oct 8, 2024
Rated: Buy
Price Target: $15
Current: $1.72
Upside: n/a
Sep 16, 2024
Rated: Buy
Price Target: $30
Current: $1.64
Upside: n/a
Sep 16, 2024
Reiterated: Buy
Price Target: $10 → $8
Current: $1.26
Upside: n/a
Aug 27, 2024
Downgraded: Hold
Price Target: $5 → $1.75
Current: $2.89
Upside: n/a
Apr 22, 2024
Initiated Coverage: Buy
Price Target: $20
Current: $2.33
Upside: n/a
Apr 8, 2024
Reiterated: Buy
Price Target: $15
Current: $6.87
Upside: n/a
May 23, 2023
Downgraded: Hold
Price Target: $15 → $1.75
Current: $0.6266
Upside: n/a
Sep 14, 2022
Reiterated: Hold
Price Target: $1.5 → $1.75
Current: $0.9063
Upside: n/a
May 31, 2022
Reiterated: Buy
Price Target: $15
Current: $1.04
Upside: n/a
May 31, 2022
Reiterated: Buy
Price Target: $6
Current: $23.25
Upside: n/a
May 12, 2022
Reiterated: Buy
Price Target: $10 → $4
Current: $18.80
Upside: n/a
Mar 9, 2022
Reiterated: Buy
Price Target: $45 → $36
Current: $19.12
Upside: n/a
Aug 21, 2020
Reiterated: Buy
Price Target: $15 → $17
Current: $0.9901
Upside: n/a
Apr 7, 2020
Reiterated: Buy
Price Target: $28 → $18
Current: $2.12
Upside: n/a